Answers are grounded in this paper and cite their sources.
Abstract ID 102601 Poster Board 071 Cardiac cytochrome P450 2J2 (CYP2J2) is pivotal in metabolizing endogenous arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs) and plays a regulatory role in cardiac electrophysiology. Our laboratory has shown previously the perturbation of CYP2J2-mediated AA-EET pathways predisposes cardiomyocytes to drug-induced proarrhythmia (1). CYP2J2*7 allele, marked by a single nucleotide substitution (G>T) in the promoter region, results in reduced promoter activity and consequently, lower plasma concentrations of stable EET metabolites (2, 3). While CYP2J2*7 has been associated with coronary artery disease, its link to proarrhythmia remains unexplored. Here, we investigate human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a suitable model to characterize the (transcriptional, translational and catalytical) consequences of CYP2J2*7 in cardiac tissue. We firstly employed hiPSCs and utilized CRISPR-directed mutagenesis to introduce the CYP2J2*7 SNP in vitro. Our optimized cardiomyocyte differentiation protocols yielded virtually pure (89-98%) CYP2J2 wild-type (WT) hiPSC-CMs and CYP2J2*7 homozygous hiPSC-CMs. Both cell types exhibited similar relative P450 epoxygenase mRNA-expression profiles consistent with human cardiomyocytes, with CYP2J2 being the dominant isozyme with minor contributions from CYP2C8 and CYP2C9. Notably, our data demonstrated that CYP2J2*7 homozygous hiPSC-CMs displayed a 40% reduction in CYP2J2 mRNA expression compared to CYP2J2 WT hiPSC-CMs. By employing a CYP2J2-selective probe substrate, ER-BnXPI (4), the successful detection of metabolite fluorescence signals from both cell types confirms functional CYP2J2 activities in vitro. Additionally, CYP2J2-mediated demethylation of astemizole was observed in both models. Compared to CYP2J2 WT hiPSC-CMs, astemizole was demethylated in CYP2J2*7 homozygous hiPSC-CMs at a similar Km value of 0.22 μM but 3-fold lower Vmax (0.20 versus 0.75 intensity·pg protein⁻¹·min⁻¹), corroborating reduced intrinsic clearance of CYP2J2*7 phenotype. Our laboratory is currently performing experiments to confirm the heightened drug-induced proarrhythmic risk associated with CYP2J2*7 using an established beat-to-beat interval assay. In conclusion, our study established CYP2J2*7 homozygous hiPSC-CMs that recapitulate the reduced mRNA expression and functional activity of CYP2J2. Our beat-to-beat interval assay will shed light on the postulated proarrhythmia phenotype associated with CYP2J2*7. References: 1. A. V. Karkhanis et al,Acta Pharmaceutica Sinica B12, 3905–3923 (2022). 2. M. Spiecker et al,Circulation110, 2132–2136 (2004). 3. L. M. King et al, Pharmacogenetics and Genomics15, 7–13 (2005). 4. X. Tian et al, Anal. Chem.94, 9572–9577 (2022).
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: